Award Data

Scarab Genomics has established a unique, tiny footprint, extended bacterial fermentation process enabled by its reduced genome E. coli, for production of protein therapeutics, especially vaccine conjugates. The process will massively reduce the cost and upgrade the quality of these critical vaccine components. This Phase IIB resubmission focuses on commercial development of Scarab’s first vacci ...

ABSTRACT The principal business interestiFIT Prosthetics LLCwith STTR fundingcreated a new transtibial prosthetic device and demonstrated its safetycomfortand functionIn contrast to conventionally made prosthetic limbsthe iFIT prosthesis is easily fit and aligned on the residual limb in a single sessionDue to its substantial adjustability and customized inner linerthe iFIT device is a comfortable ...

There is an urgent need for more effective mechanisms that leverage current technologies and best practices to both identify capacity and refer patients to drug treatment facilitiesThe applicant organizationOpenBeds Incis partnering with the non profit MESH Coalitionthree of the largest health care systems offering drug treatment in Indiana and the Indiana Division of Mental Health and AddictionDM ...

Neonatal hypoxia ischemiaHIremains a major cause of acute perinatal brain injuryleading ultimately to neurologic dysfunction manifesting as cerebral palsymental retardationand epilepsyUnfortunatelycurrent treatment and prevention strategies in newborns are limitedThere are no currently available therapies to prevent treat and or attenuate brain damage in premature infants other than supportive car ...

The primary goal of this proposed research is to develop a rapid point-of-care test that assesses the risk of neonatal sepsis (NS) and/or necrotizing enterocolitis (NEC) in infants based on Inter-alpha inhibitor proteins (IAIP) levels in blood. The test is expected to be simple, user-friendly, portable and suitable for use in the NICU. NS and NEC are associated with high mortality and morbidity, i ...

Respiratory infections with influenza viruses cause severe morbidity and mortality in humans and animals worldwideImportantlyin humansthe majority of morbidity and mortality following flu infection is seen in older individualsrtyears oldYetclear understanding of how aging impacts on innate immune responsesand how to improve vaccine design in this age group is lackingRestimulating preexisting memor ...

HLS17-12. The US FDA is considering to establish a new cardiac safety assessment approachdefined by a new paradigm called, “Comprehensive in vitro Proarrhythmia Assay (CIPA)”. The CIPA will 1) assess drug effects on each cardiac ion channel type individually using a high- throughput assay ion channel assays, 2) compute net effect on repolarization and risks fortorsade pointes (TdP) using a mat ...

The entire Research Plan contains proprietary/privileged information that Imbed Biosciences requests not be released to persons outside the Government, except for purposes of review and evaluation. SUMMARY The health care costs associated with treatment of chronic wounds exceeds $25 billion annually in the U.S. Biofilms are implicated as a key factor responsible for delayed healing. Many wounds ha ...

Thirty percent of recombinant therapeutic proteins are made in E. coli and include important vaccine components such as carrier proteins. Further, burgeoning new immunotherapies that use proteins such as single chain antibodies and virus-like particles are enjoying increasing success. To meet the production needs of these expanding areas, Scarab Genomics proposes to extend the versatility of its C ...

Scarab Genomicsgoal is to commercialize carrier proteins for conjugate vaccine manufactureThis proposal focuses on two bacterial carrier proteins that have been approved by the FDA and that are in use in pre clinical and clinical studiesExoprotein AEPAfrom Pseudomonas aeruginosa and Protein DPDfrom non typeable Haemophilus influenzaeThese proteins are difficult to make by the conventional Ecoli fe ...